CRDFCardiff OncologyCRDF info
$2.46info-3.15%24h
Global rank20727
Market cap$109.91M
Change 7d-
YTD Performance66.22%
SP500 benchmarkOutperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Cardiff Oncology (CRDF) Stock Overview

    Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and hematologic malignancies, such as KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. It primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

    CRDF Stock Information

    Symbol
    CRDF
    Address
    11055 Flintkote AvenueSan Diego, CA 92121United States
    Founded
    -
    Trading hours
    -
    Website
    https://www.cardiffoncology.com
    Country
    πŸ‡ΊπŸ‡Έ United States
    Phone Number
    858 952 7570

    Cardiff Oncology (CRDF) Price Chart

    -
    Value:-

    Cardiff Oncology Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $2.46
    N/A
    Market Cap
    $109.91M
    N/A
    Shares Outstanding
    44.68M
    N/A
    Employees
    25.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org